Valuations - current issues in biotech and pharma

Tue, 10/12/2010 - 1:20pm
3B Nexus

Dr. Andy Smith discusses valuations of profitable biotech and pharma companies relative to history, concluding that indications show biotech is too cheap at the current time. The discussion explores the PE values of various companies and how these have changed over time.

First in a series of expert analysis and commentary on the Healthcare sector. Join the discussion and leave your comments and feedback for more on this and other upcoming Global Healthcare sector topics.

You need to upgrade your Flash Player!

This web site makes use of the Macromedia Flash player 8.

VIDEO PLAYER by 3b nexus

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.